KR20150025984A - Composition for promoting hair growth or restoration containing 21-o-angeloyltheasapogenol e3 - Google Patents

Abstract

According to an aspect, the present invention relates to a composition for promoting hair growth or restoring hair comprising 21-O-angeloyltheasapogenol E3 as an active ingredient. According to another aspect, the present invention relates to a composition including 21-O-angeloyltheasapogenol E3 which promotes proliferation of hair papilla cells and hair growth in a hair follicle of a body, and reduces the growth cycle in which the suspension period is changed into growth period. More specifically, the composition comprises theasapogenol derivatives represented by chemical formula 1.

Description

COMPOUND FOR PROMOTING HAIR GROWTH OR RESTORATION CONTAINING 21-O-ANGELOYLTHEASAPOGENOL E3 [0002] The present invention relates to a composition for promoting hair growth or hair growth comprising 21-

In one aspect, the present invention relates to a composition for promoting hair growth or hair growth, and in another aspect, including 21-O-angeloyltheasapogenol E3, Which promotes hair growth by shortening the period for shortening the hair growth or hair growth promoting activity.

The causes of hair loss include male hypothyroidism, excess sebaceous glands, poor blood circulation, peroxidation, hypofunction of the scalp, genetic factors, aging, and stress. Along with the increase in social stress, the hair loss population is gradually increasing due to westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing. The cycle of hair consists of anagen which grows hair, catagen which is the period of termination of growth and reduction of the size of the moles, taloge which is the period when the papilla stops its activity and keeps its hair on the scalp, Or a generator that generates new hair to depilate old hair.

The Anagen Stage (2-7 years) is the period of hair growth, divided into hair growth stages where the hair is going to go out from the hair to the blanket and the stage where the hard keratin is made inside the hair follicle. Hair continues to self-grow until the retrogressive. Catagen Stage (2 to 3 weeks) is the period when the metabolic process is slowed down at the end of the growing season, maintaining the shape of the hair, and does not produce keratin at this stage. Degenerators account for 1% of total hair. At this time, the mothers shrink and divide into the dermal papilla, surrounded by the hair follicles and go upwards, and the cell division is stopped. The Talogen Stage (3 months) shrinks the papillary, the hair follicles shrink gradually, and the hair follicles are pushed upwards and fall out. The lifespan of the hair until the next stage of growth begins is 3 to 4 months.

A person with normal hair has a lot of hair growing, whereas a person with alopecia (Alopecia) has a lot of hair in a resting state, so that a visible hair loss phenomenon appears. As hair loss progresses, the period of growth is shortened and hair becomes smaller and smaller. Therefore, in order to treat hair loss, it is important to allow the hair follicle in a resting state to rapidly grow and to shorten the growth period.

Male alopecia are caused by testosterone, a testosterone that is converted to a more powerful hormone, Dihydrotestosterone (DHT) by an enzyme called 5-alpha-reductase. Hormone acts on the hair follicle to induce the hair follicle from the growing stage to the regenerator stage to cause hair loss. Therefore, a method of inhibiting the production of DHT by 5 alpha-reductase in order to treat male alopecia is mainly used.

Female alopecia are caused mainly by a decrease in the amount of estrogen after menopause. Minoxidil and estrogen are mainly used as therapeutic agents for female alopecia.

Alopecia areata is caused by autoimmune diseases, mental stress, genetic predisposition. These alopecia areata are fundamentally different from those of androgenetic alopecia, and different methods of treatment are used, either by a method of treating corticosteroids, or by applying minoxidil to the affected area or artificially inducing a stimulus to the affected area.

However, in the case of preparations such as minoxidil and trichosaccharide, which have been known to prevent hair loss and promote hair growth and to induce hair growth, there is a lack of clear efficacy and human stability, skin irritation And the like. Therefore, it is urgent to develop a composition having safety and efficacy.

Korean Patent Application No. 10-2008-0088127

In order to solve the above-mentioned problems, the present invention has found that 21-O-angeloyltiasapogenol E3 has an unknown effect of promoting hair growth or hair growth, And to provide a composition therefor.

In one aspect, the present invention provides a composition for promoting hair growth or hair growth, which comprises, as an active ingredient, a thiazapogenol derivative represented by the following general formula (1).

[Chemical Formula 1]

Wherein R ₁ and R ₂ are each independently -H, C _{1 -6} alkyl, -OH, -R ₆ OH or -CHO,

R ₃ is -H, C _{1 -6} alkyl, -OH, or -OOCR ₇ ,

R ₄ is -H or -COR ₈ ,

R ₅ is -H or C _{1 -6} alkyl,

Wherein R ₆ is C _{1 -6} alkyl, R ₇ is C _{2 -6} alkenyl, and R ₈ is C _{1 -6} alkyl.

In another aspect, the present invention provides a composition for promoting hair growth or hair growth comprising 21-O-angeloyltasapogenol E3 as an active ingredient.

In another aspect of the present invention, there is provided a composition for promoting hair growth or hair growth, which contains, as an active ingredient, a thiazapenol derivative derived from green tea saponin, wherein the effective ingredient is contained in an amount of 0.001 to 20 wt% to provide.

In another aspect, the present invention provides a composition for promoting hair growth or hair growth, which is a cosmetic composition, a pharmaceutical composition or a food composition.

In one aspect, the composition of the present invention contains 21-O-angioyl thiosaphenol E3 derived from green tea saponin, so that it can exhibit hair growth or hair growth promoting effect superior to conventional hair growth promoting agents.

In addition, since the plant natural material is used, it can be used as an external preparation for skin for promoting hair growth or hair growth, and can be widely used for a cosmetic composition, a pharmaceutical composition or a food composition.

In another aspect, the composition containing 21-O-angioyl thiosaphenol E3 as an active ingredient has the effect of proliferating the hair follicular dermal papilla cells, and may have an effect of inhibiting PGE2, IL-6 and IL-8 production .

Hereinafter, the present invention will be described in detail.

In one aspect, the composition of the present invention is a composition for promoting hair growth or hair growth, which contains, as an active ingredient, a thiazapogenol derivative represented by the following general formula (1).

[Chemical Formula 1]

Wherein R ₁ and R ₂ are each independently -H, C _{1 -6} alkyl, -OH, -R ₆ OH or -CHO,

R ₃ is -H, C _{1 -6} alkyl, -OH, or -OOCR ₇ ,

R ₄ is -H or -COR ₈ ,

R ₅ is -H or C _{1 -6} alkyl,

Wherein R ₆ is C _{1 -6} alkyl, R ₇ is C _{2 -6} alkenyl, and R ₈ is C _{1 -6} alkyl.

In another aspect, the composition of the present invention is a composition for promoting hair growth or hair growth comprising 21-O-Angeloyltiasapogenol E3.

In another aspect, the above-mentioned 21-O-angioyl thiosaphenol E3 may be represented by the following formula (2). That is, in Formula 1, R ₁ is -CHO, R ₂ is -CH ₃ , R ₃ is -OCOC (CH ₃ ) ═CHCH ₃ , R ₄ is -COCH _3, and R ₅ is -CH ₃ Thiazapoenol derivatives.

(2)

In another aspect, the thiazaphenol derivative represented by the above formula (1) or 21-O-angeloyl thiazophenol E3 may be 21-O-angeloyl thiosaphenol E3 derived from green tea saponin. 21-O-Angeloyltia Sapogenol E3 derived from green tea saponin is obtained from green tea seeds by using water or an organic solvent to obtain an extract containing saponin; And separating the 21-O-angioyl thiosaphenol E3 by hydrolyzing the extract with an acid, a base, an enzyme or a microorganism producing the enzyme.

The organic solvent may be at least one organic solvent selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform, or a mixture thereof with water, in one aspect, 50% ethanol. The acid may be at least one acid selected from the group consisting of hydrochloric acid, sulfuric acid and nitric acid, or a mixed solvent of the acid and at least one alcohol selected from the group consisting of ethanol, methanol and butanol. The base may be at least one base selected from the group consisting of sodium hydroxide and potassium hydroxide, or a mixed solvent of the base and at least one alcohol selected from the group consisting of ethanol, methanol and butanol. The enzyme or the microorganism producing the enzyme is a microorganism that produces an enzyme that degrades the sugar bond of the green tea saponin contained in the extract or an enzyme that degrades the sugar bond. The sugar moiety of the green tea saponin is removed to form 21- It is possible to generate sunitia Sapogenol E3. In addition, the enzyme may be selected from the group consisting of glucosidase, arabinosidase, rhamnosidase, xylosidase, cellulase, hesperidinase, And may be at least one selected from the group consisting of naringinase, glucuronidase, pectinase, galactosidase, and amyloglucosidase. Furthermore, the microorganisms producing the enzyme may be selected from the group consisting of aspergillus genus, bacillus genus, penicillium genus, rhizopus genus, rhizomucor genus, a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Bacillus,

As described above, after hydrolysis using an acid, a base, an enzyme, or a microorganism producing the enzyme, the reaction solution is concentrated under reduced pressure to remove the solvent, alcohol is added to the residue and the mixture is stirred 1 to 5 times, The obtained crude product was separated by silica gel column chromatography (chloroform: methanol = 8: 1 to 4: 1) to obtain 21- O-Angeloyltaphosanol E3 can be obtained.

In one aspect, Patent Application No. 10-2008-0088127, filed on the production process of 21-O-angioyl thiosaphenol E3 derived from green tea saponin, is incorporated herein by reference in its entirety.

The compositions disclosed herein may contain, in one aspect, from 0.001 to 20% by weight, based on the total weight of the composition, a thiazapoenol derivative or a 21-O-angioyl thiosaphenol E3 represented by formula From 0.01 to 15% by weight, from 0.01 to 10% by weight, or from 0.1 to 5% by weight. In one aspect, the thiazapenol derivative or 21-O-angioyl thiazophenol E3 represented by Formula 1 contained in the composition disclosed herein is present in an amount of 0.001% by weight or more, 0.01% by weight or more, 0.1 %, Or greater than or equal to 1.0 wt%, and in another aspect, less than or equal to 20 wt%, less than or equal to 15 wt%, less than or equal to 10 wt%, or less than or equal to 5 wt%. When the content is less than 0.001% by weight, the hair growth or hair growth promoting effect of the composition can not be expected. When the content exceeds 20% by weight, safety or formability is difficult to produce, but the content is not particularly limited.

The composition disclosed herein comprises, in one aspect, a thiazapenol derivative represented by the general formula (1) or 21-O-angeloyl thiazophenol E3, and may be a composition having an effect of proliferating a hair follicular dermal papilla. In another aspect, the composition disclosed herein comprises a thiazapoenol derivative represented by formula (1) or 21-O-angioyl thiazophenol E3, and may be a composition for activating keratin-forming cells.

The composition disclosed herein comprises, in another aspect, a thiazapenol derivative represented by the general formula (1) or 21-O-angioyl thiazophenol E3, which inhibits the production of PGE2, IL-6 or IL-8 ≪ / RTI >

In one aspect, the composition for promoting hair growth or hair growth of the present invention may be a pharmaceutical composition, a cosmetic composition or a health food composition.

In the cosmetic composition for promoting hair growth or hair growth according to an embodiment of the present invention, in addition to the thiazaphenol derivative represented by the formula (1) or 21-O-angioyl thiazophenol E3, the functional additives and the components contained in the general cosmetic composition . The functional additives may include water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

The cosmetic composition of the present invention may contain, in addition to the above-described functional additives, components contained in common cosmetic compositions as required. Examples of the other ingredients that can be included in the composition include humectants, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbents, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, Accelerators, coolants, antiperspirants, purified water, and the like.

The formulation of the cosmetic composition for promoting hair growth or hair growth according to an embodiment of the present invention is not particularly limited and may be appropriately selected according to the purpose. For example, skin lotion, skin softener, skin toner, astringent, lotion, milky lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing But the present invention is not limited thereto, and may be manufactured by any one or more formulations selected from the group consisting of a foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser.

When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

The content of the thiazapoenol derivative represented by the formula (1) or 21-O-angioyl thiosaphenol E3 contained in the cosmetic composition is not particularly limited but may be 0.001 to 20% by weight based on the total weight of the composition , And in another aspect 0.01 to 15 wt%, 0.01 to 10 wt%, or 0.1 to 5 wt%. When the active ingredient satisfies the above content, it can exhibit excellent efficacy without side effects.

The pharmaceutical composition for promoting hair growth or hair growth according to one embodiment of the present invention may contain preservatives, stabilizers, wetting agents or emulsifying accelerators, osmotic pressure control in addition to thiazaphenol derivatives or 21-O-angioyl thiazophenol E3 represented by the formula And other therapeutically useful substances, and may be formulated into a variety of oral or parenteral dosage forms according to conventional methods.

Examples of the oral administration agent include tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, powders, powders, granules, granules and pellets, , Diluents (such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (such as silica, talc, stearic acid and magnesium or calcium salts thereof and polyethylene glycols) . The tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally mixed with starch, agar, alginic acid or its sodium salt Such as disintegrants, absorbents, coloring agents, flavoring agents, and sweetening agents. The tablets may be prepared by conventional mixing, granulating or coating methods.

In addition, the parenteral administration forms may be transdermal dosage forms, and may be formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, But is not limited thereto.

The pharmaceutical composition according to one embodiment of the present invention may be administered by parenteral, rectal, topical, transdermal, subcutaneous, and the like. The pharmaceutical composition according to one embodiment of the present invention may be administered topically, for example, to the scalp.

The dosage of the active ingredient is within the level of ordinary skill in the art. The daily dose of the drug depends on various factors such as the degree of progress of the subject to be administered, the onset of the disease, age, health condition, In one aspect, the composition may be administered in an amount of 1 μg / kg to 200 mg / kg in one aspect and 50 μg / kg to 50 mg / kg in another aspect, divided into 1 to 3 doses per day, And is not intended to limit the scope of the invention in any way.

In addition, the composition for promoting hair growth or hair growth according to an embodiment of the present invention may be an external preparation for skin, and the external preparation for skin may be any kind applied to the outside of the skin, and various forms of cosmetics and medicines .

In a health food composition according to an embodiment of the present invention, the composition may be in a liquid or solid form and may be in the form of tablets, capsules, soft capsules, pills, granules, beverages (drinks), diet bars, Caramel formulation or confectionery formulation, and the formulation is not particularly limited. The health food composition of the present invention may contain excipients, saccharides, flavors, pigments, fats, proteins and the like as needed in addition to the active ingredients of 21-O-Angeloyltiasapogenol E3.

The content of thiazapenol derivative or 21-O-angioyl thiosaphenol E3 represented by the formula (1), which is an active ingredient contained in the health food composition, is not particularly limited, but may be 0.001 to 20% by weight And in another aspect 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight. When the active ingredient satisfies the above content, it can exhibit excellent efficacy without side effects.

The present invention will be described in more detail with reference to the following examples. However, the examples are for illustrating the present invention, and the scope of the present invention is not limited thereto.

[Preparation Example 1] Preparation of 21-O-angioyl thiosaphenol E3 derived from green tea saponin

Six liters of hexane were added to 2 kg of green tea seeds, and the mixture was degassed by stirring at room temperature. Then, 4 kg of 50% ethanol was added to 1 kg of the defatted green tea seeds, refluxed three times and then immersed at 15 캜 for 1 day. Thereafter, the residue and the filtrate were separated by filtration through a filter cloth and centrifugation. The separated filtrate was concentrated under reduced pressure, and the extract was suspended in water. The filtrate was extracted five times with 1 liter of ether to remove the pigment. And extracted three times with 500 ml of butanol. The total 1-butanol layer thus obtained was concentrated under reduced pressure to obtain a 1-butanol extract. The extract was dissolved in a small amount of methanol and then added to a large amount of ethyl acetate. The resulting precipitate was dried to obtain 300 g of green tea seed extract.

A 1N HCl-50% methanol solution (v / v) of 20 times (v / w) was added to 10 g of the green tea seed extract obtained above and heated and refluxed in a water bath at 80 캜 for 8 hours to bind green saponin saponin Were hydrolyzed. The reaction solution was concentrated under reduced pressure to remove the solvent, ethanol (200 ml) was added to the residue and stirred (3 times), and the precipitated salts were removed by filtration. The filtrate was concentrated under reduced pressure to obtain crude product , And the obtained crude product was separated by silica gel column chromatography (chloroform: methanol = 7: 1 to 3: 1) to obtain 21-O-angioyl thiosaphenol E3 0.55. Using Varian Gemini 2000 300 MHz (Varian), it was confirmed that the product was 21-O-Angeloyl thiosaphenol E3. The results are described in detail in Patent Application No. 10-2008-0088127, The same results as in EXPERIMENTAL EXAMPLE 1 were given.

[Test Example 1] Evaluation of expression of hair growth factor VEGF in dermal papilla cells

In order to evaluate the degree of expression of 21-O-Angeloyltia sapogenol E3 as a growth factor necessary for angiogenesis, a vascular endothelial growth factor (VEGF), which is a growth factor necessary for the transition to hair growth, After application of 21-O-Angeloyltia sapogenol E3 derived from green tea saponin by applying an in vitro system, the activity was evaluated.

For this experiment, 4 x 10 ⁵ cells of a 47-year-old male Dermal Papilla Cell (DPC) (P.11) were seeded in a 12-well plate and cultured in a 10% fetal bovine serum ) In DMEM (Dulbecco's modified Eagle's medium) overnight. After the culture, 21-O-angioyl thiosaphenol E3 derived from green tea saponin was treated with 20 ppm. As a negative control, DMSO was used. After 24 hours, the treated mixture of 21-O-angioyl thiosaphenol E3 derived from green tea saponin was collected (soup collect) and analyzed by VEGF ELISA (Vascular Endothelial Growth Factor Enzyme-Linked Immunosorbent Assay; R & D biosystems) And the degree of expression of 21-O-angioyl thiosaphenol E3 derived from E. coli. The results are shown in Table 1.

As can be seen in Table 1, 21-O-angioyltasapogenol E3 derived from green tea saponin showed a significant difference in the effect compared to the control group, and the expression of hair growth factor VEGF in the dermal papilla cells was about 3 Times. Therefore, it can be seen that 21-O-angioyl thiosaphenol E3 derived from green tea saponin according to the present invention has excellent hair growth promoting ability.

sample VEGF in culture media (ng / ml) 21-O-Angeloyltriazaphenol E3 17 Control group 5

[Test Example 2] Evaluation of proliferation effect of dermal papilla cells

The keratin proteins that make up the hair are produced in hair follicle keratinocyte, which keratinocytes differentiate from the dermal papilla cells. Therefore, if 21-O-angioyl thiosaphenol E3 derived from green tea saponin according to the present invention promotes the activity of the dermal papilla cells, the activity of the keratin-forming cells differentiated therefrom can be promoted, and furthermore, will be.

In this experiment, the promoting effect of 21-O-angioyl thiosaphenol E3 derived from green tea saponin on dermal papilla cell activity was evaluated as follows.

First, in the present invention, human dermal papilla cells (Professor Kwon Oh-Sang, Seoul National University) were used. The cells were cultured for 24 hours in an incubator maintained at 37 ° C in 5% CO ₂ with Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS) 21-O-angioyl thiosaphenol E3 derived from green tea saponin was treated at 1 ppm, 10 ppm and 20 ppm, respectively. As a negative control, DMSO was used. Cell proliferation (%) was measured using a WST-1 kit (Roche) 24 hours after treatment of the test substance. The results are shown in Table 2.

As can be seen from Table 2, 21-O-angioyl thiosaphenol E3 derived from green tea saponin according to the present invention significantly increased the proliferation of both cells at 10 ppm and 20 ppm. Particularly, when 20-pmol of 21-O-angioyl thiosaphenol E3 derived from green tea saponin was treated, the growth rate of the papillary cell proliferation was about 1.5 times higher than that of the control group. This means that 21-O-angioyl thiosaphenol E3 derived from green tea saponin according to the present invention can promote the proliferation of papillary cells and more effectively promote keratin-forming cell activity and hair generation.

sample hDPc proliferation (%) 21-O-Angeloyltriazaphenol E3
(20 ppm) 153 21-O-Angeloyltriazaphenol E3
(10 ppm) 136 21-O-Angeloyltriazaphenol E3
(1 ppm) 109 Control group 100

[Test Example 3] Evaluation of hair growth promoting effect using human hair follicular organ

Experiments were conducted to confirm the hair growth promoting ability in the actual human hair follicle organ of the present invention.

The hair follicular organ was isolated from the scalp scalp tissue of a 55-year-old male, and the hair follicle was divided into William's E medium (L-glutamine (2 mM), insulin (10 μg / ml), hydrocortisone (40 ng / ml), antibiotics %). The hair follicles grown on the third day after culturing were selected and cut into 3 mm, and the hair follicle tissues selected were treated with 1 ppm of 21-O-Angeloyltia Sapogenol E3 derived from green tea saponin, 3 ppm and 5 ppm, respectively. After 8 days from the treatment, length measurement and photographing were carried out. The results are shown in Table 3.

As a result, as shown in Table 3, treatment of 21-O-Angeloyltaphosenol E3 derived from green tea saponin at 5 ppm in hair follicle length in the hair follicle was superior to that of the control group . Therefore, it can be seen from the results of Table 3 that 21-O-angioyl thiosaphenol E3 derived from green tea saponin according to the present invention is excellent in promoting hair growth in hair follicles.

sample Average growth length (mm) 21-O-Angeloyltriazaphenol E3
(5 ppm) 2.35 21-O-Angeloyltriazaphenol E3
(3 ppm) 1.93 21-O-Angeloyltriazaphenol E3
(1 ppm) 1.62 Control group 1.56

[Test Example 4] Inhibition of PGE2, IL-6 and IL-8 production

Human fibroblasts were inoculated into 6-well culture plates at a concentration of 1 × 10 ⁵ cells and cultured in a 5% CO ₂ incubator at 37 ° C. for 24 hours. H ₂ O _{2 (} 500 μM) was added to the wells, stimulated for 24 hours, treated with calcium tree extract at different concentrations, and reacted for 48 hours. After completion of the reaction, the culture solution was collected and subjected to ELISA analysis. Alpha-bisaborol, a commonly used anti-inflammatory and anti-irritant, was used as a control. PGE2 kit was purchased from Assay Design Co., IL-6 was used from Endogen, and IL-8 was purchased from Endogen Co., and the experiment was carried out according to the method described in the manual of each company. The inhibitory effect was calculated according to the following equation (1), and the measurement results are shown in Table 4 below.

As shown in the following Table 4, the production amounts of PGE2, IL-6 and IL-8, which are inflammatory mediators, were remarkably reduced by addition of 21-O-angioyl thiosaphenol E3 derived from the green tea saponin of the present invention, Effect.

[Equation 1]

Suppression effect = {1- (test sample-control) / (H ₂ O ₂ - control)} × 100

Samples (100 ug / ml) Production inhibitory effect (pg / ml) PGE IL-6 IL-8 21-O-Angeloyltriazaphenol E3 192 170 210 H ₂ O ₂ (500 uM) 355 250 285 Control group (a-bisabolol) 271 207 269

Formulation examples of the composition according to the present invention will be described below, but the present invention can be applied to various other formulations, which are not intended to limit the present invention but to describe it specifically.

[Formulation Example 1] Shampoo

Shampoos were prepared in a conventional manner according to the composition shown in Table 5 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 Sodium lauryl sulfate 10.00 Cocamidopropyl betaine 3.00 Carboxyl vinyl polymer 0.30 Polyquaternium-10 0.20 Cetyltrimethylammonium chloride 0.10 Purified water Balance Sum 100.00

[Formulation Example 2] Rinse

Rinse was prepared according to the conventional method according to the composition shown in Table 6 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 Cetyl alcohol 2.00 Stearyl alcohol 2.50 Behenyl alcohol 0.50 Silicone emulsion 0.40 Cyclomethicone 1.00 Dimethyl distearyl ammonium chloride 0.10 Purified water Balance Sum 100.00

[Formulation Example 3] ointment

Ointment was prepared by a conventional method according to the composition shown in Table 7 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 glycerin 8.00 Butylene glycol 4.00 Liquid paraffin 15.00 Beta Glucan 7.00 Carbomer 0.10 Caprylic / capric triglyceride 3.00 Squalane 1.00 Cetearyl glucoside 1.50 Sorbitan stearate 0.40 Cetearyl alcohol 1.00 Wax 4.00 Purified water Balance Sum 100.00

[Formulation Example 4] Hair tonic

Ointment was prepared in a conventional manner according to the composition shown in Table 8 below.

ingredient Content (% by weight) ethanol 55.0 Castor oil 5.00 glycerin 3.00 Pyrrotonamine 0.10 Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 1.00 Spices, coloring Suitable amount Purified water balance Sum 100.00

[Formulation Example 5] Hair lotion

Ointments were prepared in a conventional manner according to the compositions shown in Table 9 below.

ingredient Content (% by weight) Cetostearyl alcohol 2.00 Stearyltriethylammonium chloride 2.00 Hydroxyethyl cellulose 0.50 Pyrrothonol amine 0.10 Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 10.0 Spices, coloring 0.50 Purified water balance Sum 100.00

[Formulation Example 6] Hair soap

Ointments were prepared in a conventional manner according to the composition shown in Table 10 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 5.00 Titanium dioxide 0.20 Polyethylene glycol 0.80 glycerin 0.50 Ethylenediamine tetraacetic acid 0.05 salt 1.00 Pigment Suitable amount Soap incense Suitable amount Soap base (moisture content 13%, parts by weight) to 100 Sum 100.00

[Formulation Example 7] Lotion

Lotions were prepared in a conventional manner according to the composition shown in Table 11 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Water soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice extract 0.20 1,3-butylene glycol 3.00 Purified water Balance Sum 100.00

[Formulation Example 8] Cream

Creams were prepared in a conventional manner according to the compositions shown in Table 12 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 Polyethylene glycol monostearate 2.00 Self emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-ethylhexane glyceryl 6.00 Sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water Balance Sum 100.00

[Formulation Example 9] Pack

Packs were prepared in a conventional manner according to the composition shown in Table 13 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Lauroylhydroxyproline 1.00 Water soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Balance Sum 100.00

[Formulation Example 10] Cosmetic liquid preparation

The cosmetic formulations were prepared in a conventional manner according to the composition shown in Table 14 below.

ingredient Content (% by weight) Thiazaphenol derivatives represented by the general formula (1) or 21-O-angioyl thiazophenol E3 2.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Concentrated glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 5.00 5.00 Purified water Balance Sum 100.00

[Formulation Example 11] Soft capsule

50 mg of L-carnitine, 80 mg of L-carnitine, 180 mg of soybean oil, 2 mg of palm oil, 8 mg of vegetable hydrogenated oil, 4 mg of yellow radish and 6 mg of lecithin were mixed with the thiazapoenol derivative or the 21- 400 mg / capsule was prepared according to the method to prepare a soft capsule.

[Formulation Example 12] Tablets

50 mg of the thiazaphenol derivative represented by the formula (1) or 21-O-angioyl thiazophenol E3, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose were mixed and granulated using a fluidized bed drier, 6 mg were added and tableted by tableting machine.

[Formulation Example 13]

50 mg of the thiazaphenol derivative represented by the formula (1) or 21-O-angioyl thiazophenol E3, 250 mg of anhydrous crystalline glucose and 550 mg of starch were mixed and molded into granules using a fluidized bed granulator, Respectively.

[Formulation Example 14]

50 mg of the thiazapoenol derivative represented by the formula (1) or 21-O-angioyl thiazophenol E3, 10 g of glucose, 0.6 g of citric acid and 25 g of liquid oligosaccharide are mixed and 300 ml of purified water is added to each bottle. And then sterilized at 130 DEG C for 4 to 5 seconds to prepare a beverage drink.

Claims (10)

1. A composition for promoting hair growth or hair growth comprising an effective ingredient of a thiazapogenol derivative represented by the following formula (1).
[Chemical Formula 1]

Wherein R ₁ and R ₂ are each independently -H, C _{1 -6} alkyl, -OH, -R ₆ OH or -CHO,
R ₃ is -H, C _{1 -6} alkyl, -OH, or -OOCR ₇ ,
R ₄ is -H or -COR ₈ ,
R ₅ is -H or C _{1 -6} alkyl,
Wherein R ₆ is C _{1 -6} alkyl, R ₇ is C _{2 -6} alkenyl, and R ₈ is C _{1 -6} alkyl. The method according to claim 1,
Wherein the active ingredient is 21-O-angeloyltheasapogenol E3. 3. The method of claim 2,
Wherein the 21-O-angioyl thiosaphenol E3 is represented by the following formula (2).
(2)

The method according to claim 1,
Wherein the active ingredient is derived from green tea saponin. The method according to claim 1,
Wherein the composition contains the active ingredient in an amount of 0.001 to 20% by weight based on the total weight of the composition. The method according to claim 1,
Wherein the composition has an effect of proliferating hair follicular dermal papilla cells. The method according to claim 1,
Wherein said composition has an effect of inhibiting the production of PGE2, IL-6 or IL-8. 8. The method according to any one of claims 1 to 7,
Wherein the composition is a cosmetic composition. 8. The method according to any one of claims 1 to 7,
Wherein the composition is a pharmaceutical composition. 8. The method according to any one of claims 1 to 7,
Wherein the composition is a food composition.